Ask AI
Key Trials in HR+/HER2- EBC

CE / CME

Key Ongoing Clinical Trials in HR-Positive/HER2-Negative Early-Stage Breast Cancer

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: September 22, 2022

Expiration: September 21, 2023

Activity

Progress
1
Course Completed

In this module, Denise A. Yardley, MD, reviews and discusses ongoing research that is most likely to have a clinical impact in early-stage breast cancer.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset, which can be found here or downloaded by clicking any of the slide thumbnails alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with breast cancer do you provide care for in a typical month?
Which of the following best describes how long she can wait before initiating adjuvant abemaciclib plus ET?